Dr. Arup Sen reports
MILESTONE ACHIEVED: SPROUTLY AND APOLLON FORMULARIES CONCLUDE DUE
DILIGENCE, PAVING THE WAY FOR ASSET PURCHASE AGREEMENT AND
TRANSACTION FINALIZATION
In a noteworthy development, Sproutly Canada Inc. and Apollon Formularies PLC have completed their due diligence of key assets of the companies. This marks a significant
step forward as the companies set the stage for the finalization of the asset purchase transaction.
Pending the requisite exchange and regulatory approvals, Sproutly is poised to acquire all global assets of
Apollon. The diligence and efficiency demonstrated in the due diligence phase underscore the
commitment of both companies to a seamless and expeditious transaction.
At the heart of this transaction is the consolidation of indispensable synergistic assets, intellectual
property and international intellectual property licences.
Apollon, a United Kingdom-based international natural biologics drug discovery company, has intellectual property
assets that are at the forefront of innovation in natural therapeutics, integrating cutting-edge artificial
intelligence (AI) technology. Dedicated to patient well-being, Apollon recently unveiled the successful
outcomes of third party preclinical testing, affirming the efficacy of its oncology products in combating
breast cancer and prostate cancer cells.
Specializing in natural cannabinoids, terpenes and mushroom compounds, Apollon's combinatorial
formulations, shielded by robust intellectual property protection, focus on addressing critical medical
challenges. These formulations span therapeutics for cancer, inflammatory diseases and chronic pain.
Apollon has strategically extended its reach by granting exclusive, royalty-based intellectual property
licences and sales agreements to a number of international partners. This expansion spans key regions,
including the United States, Canada, Mexico and the European Union, with recent extensions to Morocco, Israel and
South Africa.
Sproutly, a pioneering Canadian enterprise, uniquely addresses the development of natural products
with its aqueous phytorecovery process (APP). Specializing in proprietary techniques, Sproutly employs
APP to extract premium phytonutrients from cannabis and hemp, capturing their complete and
proportional profiles. What sets APP apart is its ability to yield true water-soluble formulations of natural
nutrients for medicinal applications and adult-use consumer products without resorting to artificial
chemical or physical techniques like nanoencapsulation and/or emulsification of extracted oils.
Terms of the Apollon sale
Under the terms of the binding letter of intent dated Sept. 12, 2023, now that the due diligence has been
satisfactorily completed by both companies, Sproutly will acquire the assets of Apollon pursuant to an asset purchase agreement. In exchange, Sproutly will issue to Apollon a sufficient number of Sproutly
shares so that Apollon will own 49 per cent of the enlarged share capital of Sproutly, posttransaction. If the
transaction takes place with the number of outstanding Sproutly shares as are currently in issue, and at
an anticipated deemed price of two cents (the price at which the trading of common shares of Sproutly
was suspended), the effective valuation of the disposal of Apollon's assets will be $7-million
(approximately 4.2 million pounds sterling). If the number of Sproutly shares increases between now and the date of the
transaction, the number of shares to be issued to Apollon will increase accordingly.
Dr. Arup Sen, chief executive officer of Sproutly, stated: "I am delighted to announce the successful completion of this due
diligence phase with Apollon, marking a key milestone in our journey towards finalizing the asset purchase
agreement. The progress reflects our shared commitment to efficiency and diligence in navigating this
transformative transaction. The integration of Apollon's cutting-edge AI-based therapeutic formulations
development and Sproutly's APP technology to produce water-soluble phytonutrients presents a unique
opportunity. This collaboration signifies not just a milestone but a commitment to global innovation and
diversification of our product portfolio. I look forward to working with Dr. Stephen Barnhill and his expert
team where together, we aim to pioneer the development of unique water-soluble natural biologic
products, setting new standards in enhanced bioavailability, innovative consumer products for adult use,
therapeutic products that use reduced dosage and extended product shelf life."
Dr. Barnhill, MD, chairman and CEO of Apollon, expressed: "I am thrilled to move ahead with the
transaction, enabling Sproutly to acquire Apollon's assets. The convergence of assets held by both
companies is poised to showcase that the collective synergy surpasses the sum of individual components.
These combined assets encompass a spectrum of synergistic drug discovery technologies, pending
patents and proprietary intellectual property. We bring to the table successful preclinical and clinical
testing, cutting-edge manufacturing and production laboratories, and a network of exclusive, royalty-based global licences and sales agreements across a number of countries, promising the potential of
substantial royalty revenue. Together, we possess the capability to pioneer the development of novel
combinatorial therapeutic products. Collaborating with Dr. Arup Sen, I am enthusiastic about shaping
what I believe will be a leading natural biologics drug discovery company, focused on creating innovative
therapeutic products for imminent international distribution and sales."
It is important to note that the completion remains contingent upon customary closing conditions, as well
as exchange and regulatory approvals, and final due diligence for the period to the date of transaction
completion. Further details regarding the transaction and its implications for both companies will be
disclosed in subsequent updates.
About Sproutly Canada Inc.
Sproutly is pursuing commercialization of aqueous phytorecovery process (APP) technology through
partnerships in Canada, the EU, Australia, Jamaica and Israel -- the territories where Sproutly has licensed the
rights from Infusion Biosciences Inc. Whole plant water-soluble Infuz2O and BioNatural Oils produced by
using APP deliver unique effects of different cannabis strains to produce differentiated consumer
products in beverage, edible and topical formulations.
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.